HIT-CF New clinical trial design in Cystic Fibrosis

Similar documents
We strive to develop innovative solutions that improve and extend the lives of people with cystic fibrosis

Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis

Phase 1 and 2 Data for Triple Combination Regimens Demonstrate Improvements in Lung Function and Other Measures in CF Patients

Cost-effectiveness of Ivacaftor (Kalydeco ) for the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Supplementary appendix

North American Cystic Fibrosis Conference 27 October Noreen R Henig, MD Chief Development Officer ProQR Therapeutics

North American Cystic Fibrosis Conference 27 October Noreen R Henig, MD Chief Development Officer ProQR Therapeutics

Transformational Treatments. PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs

Enabling CF Therapeutic Development

Brand Name: Kalydeco. Generic: ivacaftor. Manufacturer 1 : Vertex Pharmaceuticals Incorporated

A Genetic Approach to the Treatment of Cystic Fibrosis

PA Update: Oral Cystic Fibrosis Modulators

Orkambi. Orkambi (lumacaftor/ivacaftor) Description

GLPG1837 in Subjects with Cystic Fibrosis (CF) and the G551D Mutation: results from a Phase II study (SAPHIRA1)

Phase 3 EVOLVE & EXPAND Studies of Tezacaftor/Ivacaftor Combination Show Statistically Significant Improvements in Lung Function and Other Measures

TRANSPARENCY COMMITTEE

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Oral Cystic Fibrosis Modulators

ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: October 3, ClinicalTrials.gov ID: NCT

The Future of CF Therapy

Case Study What is the Relationship Between the Cell Membrane and Cystic Fibrosis?

Symdeko. Symdeko (tezacaftor and ivacaftor) Description

A Case of Cystic Fibrosis

HOW DISEASE ALTERING THERAPY IS CHANGING THE GOALS OF TREATMENT IN CF

NACFC investor meeting. Dr Katja Conrath, Therapeutic Head CF Dr Piet Wigerinck, CSO NACFC November 2017 Copyright 2017 Galapagos NV

PART VI Summary of the RMP

THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)

Cystic Fibrosis Foundation Patient Registry 2013

Kalydeco. Kalydeco (ivacaftor) Description

CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION

Clinical Trials for Rare Diseases in CDER

Targeted therapies to improve CFTR function in cystic fibrosis

CYSTIC FIBROSIS CANADA S CF PHYSICIAN PANEL ON LUMACAFTOR/IVACAFTOR: RECOMMENDATIONS FOR CRITERIA FOR CLINICAL USE

CF: Understanding the Biology Curing the Disease

Molecular Basis of Personalized Therapies for CF: Can We Treat All Patients?

Class Update with New Drug Evaluation: Oral Cystic Fibrosis Modulators

ivacaftor 150mg film-coated tablets (Kalydeco ) SMC No. (1193/16) Vertex Pharmaceuticals (Europe) Ltd

Cystic Fibrosis: Progress in Treatment Management. Patrick A. Flume, M.D. Medical University of South Carolina

New Drug Evaluation: Lumacaftor/Ivacaftor

Novel targets, better treatments

UNDERSTANDING THE EARLY, SYSTEMIC PROGRESSION OF CYSTIC FIBROSIS (CF) A Resource for the CF Center Care Team

Pharmacy Policy Bulletin

Cystic fibrosis (CF) is the most frequent. Ivacaftor treatment in patients with cystic REVIEW. Isabelle Sermet-Gaudelus

Class Update: Oral Cystic Fibrosis Modulators

Supplementary appendix

Exploring New Advances and Best Practices to Personalize Therapy and Improve Lung Function in Cystic Fibrosis

"Management and Treatment of Patients with Cystic fibrosis (CF)

Briefing Document. FDA Pulmonary - Allergy Drugs Advisory Committee

4.6 Small airways disease

Report on Enpr-EMA workshop on gastrointestinal (GI) outcome measures to evaluate CFTR modulators for the treatment of cystic fibrosis (CF)

Disclosures. Advances in the Management of Cystic Fibrosis: A Closer Look at the Roles of CFTR Modulation Therapy 10/28/2016

Scottish Paediatric Cystic Fibrosis MCN. Protocols / Guidelines. Ivacaftor: A guideline for use in paediatric CF patients in Scotland

Fungal (Aspergillus and Candida) infections in Cystic fibrosis

CYSTIC FIBROSIS OBJECTIVES NO CONFLICT OF INTEREST TO DISCLOSE

Key Points: References: Canadian data from the Canadian Cystic Fibrosis Registry 2015 Annual Report normal

A treatment option for patients with CF who have responsive mutations

Characterizing aggressiveness and predicting future progression of CF lung disease

Opinion 7 November 2012

Improved repeatability of nasal potential difference with a larger surface catheter

DIS News. Literature Highlight: Vismodegib in Patients with Basal-Cell Nevus Syndrome. Inside this issue: August 2012

Dear Dr. Herink and Members of the Pharmacy and Therapeutics Committee:

Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects

Pediatrics Grand Rounds 18 Sept University of Texas Health Science Center. + Disclosure. + Learning Objectives.

Liver Forum Cirrhosis Working Group Arun J. Sanyal

Drug Class Literature Scan: Pancreatic Enzymes

IVACAFTOR THE ISRAELI EXPERIENCE ADI DAGAN MD THE ISRAELI CF CENTER SHEBA MEDICAL CENTER, TEL-HASHOMER

Initiation Guide. Images not actual size.

Title: Lack of correlation between pulmonary disease and CFTR dysfunction in cystic fibrosis -- the case of 3791delC

The role of serum Pseudomonas aeruginosa antibodies in the diagnosis and follow-up of cystic fibrosis

The role of Pulmonary function Testing In Interstitial lung disease in infants. [ ipft in child ]

Timely Topics in Pulmonary Medicine

Intestinal Stem Cells And Organoids

Clinical Commissioning Policy: Ivacaftor for Cystic Fibrosis (named mutations)

Modulator Treatments for Cystic Fibrosis: Effectiveness and Value

ANALYST & INVESTOR EVENT NACFC 2016, Orlando, Florida

CYSTIC FIBROSIS (CF): THE CHALLENGE OF EARLY, SYSTEMIC PROGRESSION

Cystic Fibrosis the future

A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference

CYSTIC FIBROSIS FOUNDATION INFO-POD Information You Need to Make Benefits Decisions

Correspondence: Dr Sushil K. Kabra, Professor, Department of Pediatrics, AIIMS, New Delhi , India.

confirmatory clinical trials - The PMDA Perspective -

Long term azithromycin therapy in patients with cystic fibrosis

GET TO KNOW ORKAMBI. WHAT IS ORKAMBI (lumacaftor/ivacaftor)? IMPORTANT SAFETY INFORMATION

Cystic Fibrosis a) Diagnostic Dilemmas b) The New Problems. Dr Mark Rosenthal Royal Brompton Hospital London

Cystic fibrosis: From childhood to adulthood. Eitan Kerem Department of Pediatrics and CF Center Hadassah University Hospital Jerusalem Israel

You Can Observe a Lot By Just Watching. Wayne J. Morgan, MD, CM

The Deciphering Development Disorders (DDD) project: What a genomic approach can achieve

Disclosures. Learning Objectives. What is Cystic Fibrosis? Background

Cystic Fibrosis 8/23/2014 GROWTH DEFICIENCY IN CYSTIC FIBROSIS IS

THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)

Clustering of rare medical conditons based on applicability of methods and designs for clinical trials

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION KALYDECO. Ivacaftor tablets 150 mg Ivacaftor granules 50 mg per packet, 75 mg per packet

ORIGINAL ARTICLE. Cystic fibrosis. Key messages

Big data vs. the individual liver from a regulatory perspective

TITLE: Dornase Alfa for Patients with Cystic Fibrosis: A Review of the Clinical Efficacy and Cost-Effectiveness

Time Point to Perform Lung Function Tests Evaluating the Effects of an Airway Clearance Therapy Session in Cystic Fibrosis

The Role of CPET (cardiopulmonary exercise testing) in Assessing Lung Disease in CF

Transcription:

HIT-CF New clinical trial design in Cystic Fibrosis Peter van Mourik, MD, PhD-student Pediatric Pulmonology, University Medical Center Utrecht, the Netherlands

Contents - Difficulties of clinical trials in Cystic Fibrosis population - Our solutions to these difficulties

Difficulty 1: CF patient population > 2000 CFTR-mutations HIT-CF F508del/F508del Lumacaftor/Ivacaftor (Triple therapy) Gating Ivacaftor (Novel potentiators)

Rare disease, considerable heterogeneity Disease severity Differs per mutation Considerable differences within genotype

Drug efficacy - Target is different per CFTR-mutation Target is unknown for rare mutations Efficacy of drugs cannot be predicted in these patients Heterogeneity in treatment response makes clinical trial very difficult

Solution: stratifying patients

Organoid model to identify drug response Healthy control F508del/F508del F508del/F508del Lumacaftor/Ivacaftor CFTR-activating stimulus (fsk)

Using organoids to select the best responding patients

Identifying our patient population 500 biopsies European CFpatients Test drugs of three pharmaceutical companies on these organoids Select the best responders per drug

Difficulty 2: FEV1 as EMA-approved endpoint Forced Expiratory Volume in 1 second FEV1 as surrogate for mortality usually required by EMA as primary endpoint for most pulmonary indications. At present, FEV1, despite its major limitations, still remains an important outcome measure for clinical efficacy. Report of the workshop on endpoints for cystic fibrosis, European Medicines Agency, 2012

Difficulties of spirometry (FEV1) - Baseline value influences the potential for change Starting with 100% predicted FEV1 -> less potential to increase by another 10% - Within subject standard deviation of 4.5%-6.3% ppfev1 - Efficacy of known drugs: 4-8% ppfev1 improvement - Limited patient population Stanbrook 2004, Chest Cooper 1990, Pediatr Pulmonol Taylor-Robinson 2012, Thorax

Solution (1): Tackling the high endpoint variability Placebo-controlled crossover design Decreasing the influence of within-patient variability Decreasing the influence of between-patient variance Repeated measurements Decreasing the influence of within-patient variability

Solution: Other valid primary endpoints? Sweat Chloride Concentration In-vivo measurement of CFTR-function could confirm the expected mechanistic effect at patient level In theory representative of systemic drug effects Could be used as intermediate endpoint (or biomarker)

Sweat chloride concentration In-vivo measurement of CFTR-function

Sweat Chloride Concentration Elevated in CF-patients, normal in healthy subjects Large potential for change Effect of Ivacaftor on SCC STRIVE-trial What is a Clinically significant change? the effect of the compound on biomarkers such as sweat chloride that directly measure CFTR function, can be considered as intermediate proof of efficacy. Vermeulen 2016, Journal of Cystic Fibrosis Report of the workshop on endpoints for cystic fibrosis, European Medicines Agency, 2012

Correlation between Sweat Chloride and FEV1 Sweat chloride is useful in multicenter trials as a biomarker of CFTR activity and to test the effect of CFTR potentiators. Sweat chloride is not a useful marker of clinical response to Ivacaftor Sweat chloride level changes in response to potentiation of the CFTR protein by Ivacaftor appear to be a predictive pharmacodynamic biomarker of lung function changes on a population basis but are unsuitable for the prediction of treatment benefits for individuals. Accurso 2014, Journal of Cystic Fibrosis Barry 2014, Thorax Fidler 2016, Journal of Cystic Fibrosis

Sweat Chloride as co-primary outcome Provide mechanistic evidence of efficacy Useful for future trials in smaller populations FEV1 effect possibly not large enough

Difficulty 3: increasingly small trial population CF-patient population becomes more dispersed Need for effective n-of-1 trial design/outcome parameters

HIT-CF exploratory endpoint Within-patient comparative assessment of response to treatment assess whether the observed difference between treatment and placebo for an individual patient is sufficiently larger than the measurement uncertainty for an individual patient. These data can be used for the design of future n-of-1 trials

Difficulty 4: Validate organoids as predictive model Several trials are running to evaluate the predictive capacity of organoids If we only include in vitro responders, we cannot evaluate predictive potential Ethically problematic to include large numbers of predicted non-responders?

Solution 4: platform trial for overarching analysis 15 low organoid responders can be compared to 60 high organoid responders because of platform design

HIT-CF: enhanced clinical trial design in a heterogeneous, small population Using in-vitro model to stratify patients Cross-over design with repeated measurements to increase power Generating data to be used for future n-of-1 trials Validating in-vitro model

Acknowledgements University Medical Center Utrecht Pediatric Pulmonology Kors van der Ent Sabine Michel Gitte Berkers Jeffrey Beekman Florijn Dekkers University Medical Center - Julius Center for Health Sciences and Primary Care Kit Roes Stavros Nikolakopoulos Konstantinos Pateras Sjoerd Elias Katholieke Universiteit Leuven Kris de Boeck Julius Clinical Hans van Dijk Gerard Krielen Biotechsubsidy Marc van de Craen